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INTRODUCTION
In most metazoans, the majority of polymerase II (Pol II)-transcribed genes are regulated at a step called promoter-proximal pausing (Chen et al., 2018; Jonkers and Lis, 2015) . Release from pausing requires phosphorylation of the Pol II C-terminal domain (CTD) by cyclin-dependent kinase 9 (CDK9)-containing positive transcription elongation factor b (P-TEFb) (Peterlin and Price, 2006; Zhou et al., 2012) . Proper regulation of this transcriptional checkpoint is vital for physiological responses in metazoan development, and misregulation of this checkpoint has been found to contribute to human diseases, including cancer Bradner et al., 2017; Shilatifard et al., 1996; Smith et al., 2011; Takahashi et al., 2011) .
The majority of P-TEFb, comprising CDK9 and its cyclin partner Cyclin T1 (CCNT1), is sequestered in an inactive form by RNA binding proteins HEXIM1 or HEXIM2 associating with 7SK small nuclear ribonucleoprotein particle (snRNP) (Luo et al., 2012a; Zhou et al., 2012) . The inactive complex occupies promoterproximal regions on chromatin (Ji et al., 2013; McNamara et al., 2016) . P-TEFb can be released from the 7SK/HEXIM complex into active complexes such as BRD4/P-TEFb (Yang et al., 2005) and the super elongation complex (SEC) Luo et al., 2012b; Zhou et al., 2012) . Inhibition of all P-TEFb activity can be achieved with inhibitors such as flavopiridol (Chao and Price, 2001) . The activity of BRD4/P-TEFb can be inhibited with small molecules blocking its recruitment to chromatin (Dawson et al., 2011; Filippakopoulos et al., 2010) and phthalimideconjugated analogs can induce rapid degradation of BRD4 (Winter et al., 2015 (Winter et al., , 2017 . Blocking BRD4/P-TEFb with these compounds inhibits release of paused Pol II into productive elongation with profound effects on MYC targets (Bradner et al., 2017; Delmore et al., 2011) . However, studies of SEC in cells are more limited due to a lack of small molecular inhibitors specifically targeting this form of P-TEFb.
In addition to P-TEFb, SEC contains AF4/FMR2 (AFF) family proteins (AFF1-4), the YEATS domain-containing proteins ENL or AF9 (encoded by the MLLT1 and MLLT3 genes), the Pol II elongation factors eleven-nineteen lysine-rich leukemia (ELL) proteins, and ELL-associated factor 1 (EAF1) or EAF2 Chen et al., 2018; Luo et al., 2012b) . Within SEC, the AFF proteins function as scaffolds for binding the other subunits. P-TEFb is required for phosphorylation of Pol II CTD on serine 2 (Ser2P) and transcription elongation factor SPT5 on its C-terminal region to promote release from the promoter-proximal pausing, while ELL proteins have been demonstrated to enhance processivity of elongation by RNA Pol II using in vitro transcription assays (Shilatifard et al., 1996 (Shilatifard et al., , 1997 and in cells (Hu et al., 2013) .
SEC is required for rapid induction of transcription in response to cellular signals (Galbraith et al., 2013; Lin et al., 2010 Lin et al., , 2011 Takahashi et al., 2011) and is hijacked by HIV Tat to activate proviral genome transcription (He et al., 2010; Sobhian et al., 2010) . Mistargeting of SEC is essential for leukemogenesis driven by rearrangements of the mixed lineage leukemia (MLL) gene Mohan et al., 2010; Yokoyama et al., 2010; Lin et al., 2010) . Mutations that stabilize SEC lead to the developmental syndrome CHOPS (cognitive impairment and coarse facies, heart defects, obesity, pulmonary involvement, and short stature and skeletal dysplasia) (Izumi et al., 2015) . SEC is a regulatory factor of MYC Luo et al., 2012a; Takahashi et al., 2011; Wan et al., 2017) , which is a master regulator for cancer cell proliferation and contributes to the pathogenesis of a majority of human cancers by coordinated amplification of transcription (Lin et al., 2012; Nie et al., 2012; Sabò et al., 2014; Walz et al., 2014) and is particularly required for expression of cell division and pre-mRNA splicing factors (Hsu et al., 2015; Koh et al., 2015) . Given the importance of transcription elongation control in cancer pathogenesis and the paradigm of BET domain inhibitors in targeting MYC expression and the transcriptional elongation misregulation in cancers (Bradner et al., 2017) , developing inhibitors of SEC can serve as a tool for both mechanistic studies of SEC and for cancer therapeutics.
RESULTS

Peptidomimetic Identification of Disruptors of SEC
To identify small-molecule disruptors of SEC, we first examined the crystal structure (PDB: 4IMY) showing AFF4 bound to the CCNT1 subunit of P-TEFb (Gu et al., 2014; Schulze-Gahmen et al., 2013) . Five residues of the N terminus of AFF4 (L34, F35, A36, E37, and P38) interacted with the binding groove of CCNT1, comprising the residues W221, Y224, L163, V164, R165, Y175, F176, D169, W207, W210, and E211 ( Figure 1A) . Mutation data of CCNT1 residues Y175, E211, D169, F176, R165, W210, and W207 demonstrated the importance of this pocket for interactions with AFF4 (Schulze- Gahmen et al., 2013) . A three-tiered grid-based ligand docking glide algorithm was employed to screen for potential compounds binding to the CCNT1 binding pocket ( Figure 1A) .
To test whether candidate compounds can disrupt the AFF4-CCNT1 interaction in vitro, we used a bead-based AlphaLISA Figure 1 . Peptidomimetic Identification of Disruptors of the AFF4-CCNT1 Interaction within SEC (A) Schematic for identifying small-molecule disruptors of the AFF4-CCNT1 interaction using in silico screening. Compounds from the ZINC database were docked with the AFF4-CCNT1 structure (4IMY) using a three-tier glide-docking algorithm, which led to 40 candidates. Residues in the binding pocket of CCNT1 are labeled orange, and residues of the AFF4 peptide are labeled red. (B) Validation screening identified KL-1 as a potential SEC disruptor using AlphaLISA screening. GST-CCNT1 (aa 1-300) and biotin-labeled AFF4 peptide (aa 32-67) were used to measure the AFF4-CCNT1 interaction with the AlphaLISA assay. Data are represented as mean ± SD. (C) Similarity search for KL-1-like molecules identified KL-2. The peptidomimetic potential of KL-1 and KL-2 can be seen by overlaying them with the AFF4 peptide LFAEP structure. (D) Dose-dependent inhibition of KL-1 and KL-2 on AFF4-CCNT1 interaction. The K i constants of both compounds were measured with the AlphaLISA assays. Data are represented as mean ± SD. (E) KL-1 and KL-2 treatment results in reduced protein levels of SEC components AFF1 and AFF4 but not CDK9 or CCNT1. HEK293T cells were treated with 20 mM of SEC inhibitors KL-1 or KL-2 for 6 hr. 5-, 10-, and 20-mL cell lysates were loaded, and the protein levels of AFF1, AFF4, CCNT1, CDK9, and Tubulin (load control) were determined by western blotting. (F-H) ChIP-seq analysis demonstrates that KL-1 and KL-2 treatment results in decreased occupancy of AFF1 and AFF4 on chromatin as seen at the HSPA8 gene (F) or by metaplot analysis at AFF1 (G) and AFF4 peak regions (H) . See also Figure S1 . assay with recombinant CCNT1 protein and synthesized Biotin-AFF4 peptides (amino acid [aa] 32-67) (Figures S1A-SC). We tested the 40 compounds identified from the in silico screening at 20 mM with the AlphaLISA assay ( Figure 1B) and found that the compound (2Z)-N-(5-chloro-2-methylphenyl)-2hydroxy-4-(3-methoxyphenyl)-4-oxo-2-butenamide, referred to as ''KL-1'' ( Figure 1C ), could inhibit the interaction of AFF4-CCNT1, while neither the pan-CDK9 kinase inhibitor flavopiridol nor the BET domain inhibitors disrupted the AFF4-CCNT1 interaction ( Figure 1B) .
Based on the structure of KL-1 ( Figure 1C ), we performed a KL-1 similarity search with ChemDiv compounds and tested the top 32 most similar compounds. The compound (2Z)-N-(5chloro-2-methylphenyl)-4-(4-fluorophenyl)-2-hydroxy-4-oxo-2butenamide (referred to as ''KL-2'') shares the same scaffold as KL-1, and modeling of their structures reveals similar peptidomimetic potential for the AFF4 pentapeptide LFAEP (leucinephenylalanine-alanine-glutamic acid-proline) ( Figure 1C ). Both compounds exhibited dose-dependent inhibitory effects on the AFF4-CCNT1 interaction with observed K i of 3.48 mM and 1.50 mM, respectively, for KL-1 and KL-2 ( Figure 1D ). In order to study the functions of KL-1 and KL-2 in depth, we synthesized these compounds in house as shown in Figure S1D .
KL-1 and KL-2 treatments led to depletion of SEC components AFF1 and AFF4 in both HEK293T and HCT-116 cells within 6 hr (Figures 1E, S1E, and S1F), but no major effect on the protein levels of P-TEFb components CCNT1 and CDK9, or on Pol II, BRD2, and BRD4. We confirmed that treating cells with these two compounds results in decreased AFF1 and AFF4 protein using doxycycline-inducible Flag-AFF1 and Flag-AFF4 HEK293T cells (Figures S1G and S1H). KL-1 and KL-2 treatments do not result in decreased mRNA levels of SEC components ( Figure S1I ). Together, these data demonstrate that KL-1 and KL-2 disrupt the interaction of CCNT1 and the SEC scaffolding AFF proteins, which results in reduced levels of cellular SEC. To investigate the consequences of AFF1 and AFF4 protein reduction on their association with chromatin, we performed chromatin immunoprecipitation sequencing (ChIP-seq) of AFF1 and AFF4 in HEK293T cells treated with KL-1 and KL-2 for 6 hr. Genome browser views of the HSPA8 gene demonstrate that both inhibitors lead to decreased occupancy of AFF1 and AFF4 ( Figure 1F ) and reduced AFF1 and AFF4 chromatin occupancy is observed by genome-wide analysis ( Figures 1G and 1H ).
Small-Molecule Disruption of SEC Increases Promoter-Proximal Pausing
Treatment of cells with KL-1 and KL-2 resulted in increased Pol II occupancy at the promoter-proximal regions of HSPA8 and SRSF4 loci ( Figure 2A ). Analysis of the 6,119 Pol II occupied genes in HEK293T cells that are also occupied by AFF1 or AFF4 showed that these genes have increased Pol II occupancy at the promoter-proximal regions after treatment of KL-1 and KL-2 ( Figure 2B ). We also tested the SEC inhibitors in HCT-116 and Jurkat (J-Lat 6.3 clone) (Jordan et al., 2003) cells and observed similar increases of Pol II occupancy in promoter-proximal regions ( Figures S2A-S2C ).
To further investigate the relationship between Pol II and SEC occupancy changes due to SEC inhibitor treatments, we used k-means clustering with the 6,119 Pol II and SEC-occupied genes to generate three groups: group I, II, and III ( Figure S2D ). Group I genes exhibited the highest fold-change increase in Pol II occupancy and have the highest AFF1 ( Figure S2E ) and AFF4 ( Figure S2F ) occupancy in the control condition, suggesting that the increased Pol II occupancy by KL-1 and KL-2 can be attributed to changes in SEC occupancy. Scatterplot analysis shows that KL-1 ( Figure 2C ) and KL-2 ( Figure 2D ) globally reduce AFF1 and AFF4 occupancy (leftward shift) and increases Pol II occupancy (upward shift) at co-occupied genes, suggesting that disruption of SEC by small molecules leads to increases in promoter-proximal Pol II occupancy.
We calculated levels of Pol II pausing based on the ratio of Pol II reads in the gene body and promoter ( Figure 2E ). Analysis of pausing index revealed that SEC disruptors KL-1 and KL-2 could increase promoter-proximal pausing as shown by the empirical cumulative distribution function (ECDF) plot (Figure 2F) . ECDF analysis of pausing indexes in HCT-116 and Jurkat cells showed similar effects as seen in HEK293T (Figures S2G and S2H) , demonstrating that SEC inhibition leads to increased promoter-proximal pausing. To further demonstrate that SEC inhibition through KL-1 and KL-2 increases pausing at the early stage of transcription elongation, we depleted AFF1 and AFF4 proteins in HEK293T cells with short hairpin RNAs (shRNA) and found that co-knockdown of AFF1 and AFF4 leads to increased Pol II occupancy in promoter-proximal regions, as can be seen at the SRSF4 gene ( Figure 2G ) and by ECDF analysis ( Figure 2H ) similar to the use of KL-1 and KL-2 ( Figure 2F ).
Disruption of SEC Phenocopies Slow Pol II Mutants
Examination of Pol II changes at the 3 0 end of genes, such as SRSF4 and HSPA8, revealed a 5 0 end shift of Pol II from the transcription termination sites (Figures S2I and S2J) , which is reminiscent of the recently published phenotype of slow Pol II mutants ( Figure 3A ) (Fong et al., 2015) . Therefore, we tested the effect of KL-1 and KL-2 treatments with the Pol II speed mutant cells generously provided by the Bentley laboratory (University of Colorado). KL-1 and KL-2 treatments shift the Pol II profile downstream of the TES more 5 0 in the fast, wild-type (WT) and slow Pol II mutant cells at the ACTB and PIM3 gene ( Figures 3B and 3C ). Performing genome-wide analysis of genes with Pol II termination signals around the TES sites ( Figure S3A ), we observed similar Pol II profiles observed by Bentley and colleagues in the slow and fast Pol II cells ( Figure 3D ) (Fong et al., 2015) . Treatment of fast Pol II mutant cells with SEC inhibitors leads to a similar Pol II pattern as the slow Pol II mutant, with a 5 0 shift in read coverage at the 3 0 end of genes (Figures 3D, 3E, and S3B) , indicating that disruption of SEC phenocopies slow Pol II mutants. To further verify these phenotypes, we performed time-and dose-dependent treatment of KL-2 in the 293T cells and observed dose-and time-dependent 5 0 shifts of Pol II signal around TES sites (Figures S3C and S3D) .
Since slow Pol II mutants exhibited hyperphosphorylation of the CTD on Ser2 at the 5 0 end of genes due to higher ''dwell time'' (Fong et al., 2017) , we asked whether SEC inhibitor treatments mimicked this phenotype as well. We performed ChIPseq for the Ser2P form of Pol II in HEK293T cells after 6 hr of KL-1 and KL-2 treatments and observed that KL-1 or KL-2 elevates Pol II Ser2P levels around transcription start sites and their downstream regions, as can be seen at the SRSF1 gene (Figure S3E) and by metagene analysis of Pol II Ser2P changes (Figures S3F and S3G) , further suggesting KL-1 and KL-2 treatments could slow down Pol II transcription elongation.
Since both ELL and the related ELL2 were originally biochemically and mechanistically identified to function as transcription elongation factors to regulate the processive rate (V max ) of transcription elongation in vitro (Shilatifard et al., 1996; 1997) and KL-1 and KL-2-treated cells exhibited phenotypes indicative of less processive Pol II, we therefore measured ELL2 protein levels after KL-1 and KL-2 treatments. We found that KL-1 and KL-2 led to reduced ELL2 protein levels in cells ( Figure S3H ), suggesting that ELL2 reduction may account for the observed slow-down of Pol II elongation rate (Figures 3E and S3B) . To test this, we depleted ELL2 in HEK293T cells ( Figure S3I ) and found a 5 0 shift S3L ) similar to the KL-1 and KL-2 treatments or the slow Pol II mutant, albeit to a lesser extent. Together, these data suggest that ELL2 reduction contributes to the slow Pol II phenotypes resulting from KL-1 and KL-2 treatments.
To better delineate changes in Pol II occupancy in response to KL-1 and KL-2, we performed precision nuclear run-on and sequencing (PRO-seq) (Kwak et al., 2013) , which allows singlenucleotide resolution of polymerase position (Figures 3F and 3G) . PRO-seq analysis confirmed that KL-1 and KL-2 treatments result in increased promoter-proximal pausing ( Figures S3M and  S3N ). Increased occupancy of engaged Pol II in the gene body, particularly at the 3 0 end of genes as can be seen by metagene analysis (Figures 3H and 3I ). Heatmap analysis of expressed genes ranked by gene length is consistent with KL-1 and KL-2 treatments reducing Pol II processivity, which in turn leads to premature termination due to slower transcription elongation of Pol II ( Figure 3H ). Furthermore, PRO-seq analysis confirms a 3 0 end transcriptional defect ( Figures 3H and 3J) , which is consistent with the Pol II profiles observed in the slow Pol II mutant cells. Metaplots of Pol II ChIP-seq coverage at the 3 0 end of genes in the fast, WT, and slow Pol II mutant cells. The region from TES to 7.5 kb downstream of the TES for the 1,057 genes with typical Pol II termination signals in HEK293T cells is plotted ( Figure S3A ). Pol II appears to terminate earlier in the R749H slow Pol II mutant relative to WT Pol II cells, while the E1126G fast Pol II mutant appears to have a delayed termination with a less prominent peak of Pol II signal 3 0 of the TES. (E) Treatment of the fast Pol II-mutant-expressing cells with SEC inhibitors leads to a Pol II phenotype similar to slower Pol II-mutant-expressing cells as viewed at the 3 0 end of genes. 
Disruption of SEC by KL-1/KL-2 Slows Pol II Elongation Rates
To measure the consequence of SEC inhibition on the rate and processivity of transcription elongation, we used a 4sU-FP-seq strategy employing flavopiridol (FP)-induced pausing followed by release in the presence of 4sU (Fuchs et al., 2014 ) ( Figure 4A ). When cells are pretreated with KL-1 and KL-2, the distance Pol II traveled after release from flavopiridol was markedly reduced, as seen at individual genes ( Figure 4B ) and by heatmap ( Figure 4C ) and metaplot analysis ( Figure 4D ). We used two different approaches to measure elongation rates in the 4sU-FP-seq experiments as the result of KL-1 and/or KL-2 treatment. First, we employed a Hidden Markov model (HMM) method for calculating elongation rates . We were able to measure elongation rates across all samples for 982 genes (the number of genes for which the model could detect a wave front of Pol II elongation). This analysis demonstrated that both KL-1 and KL-2 treatments decreased the elongation rate of Pol II at the ACTN2 and MTR genes (Figures 4E and S4A) , and globally as can be seen by boxplot and histogram analyses of these 982 genes ( Figures 4F and 4G ). Second, we used the island-based peak caller SICER to use the width of peaks overlapping transcription start site (TSS) regions to measure distance traveled ( Figures S4B-S4E ). Together, these data suggest that KL-1/KL-2-dependent disruption of SEC results in slower elongating Pol II.
SEC Inhibitors Block Paused Pol II Release in SEC-Dependent Rapid Response Models
SEC has been shown to mediate transcription elongation in rapid response models such as heat-shock-induced gene expression Takahashi et al., 2011) and Tat-induced HIV proviral transcription (He et al., 2010; Sobhian et al., 2010) . Therefore, we tested whether KL-1 and KL-2 could inhibit the function of SEC in these rapid-response models. For heat shock induction, we pretreated HCT-116 cells with KL-1 or KL-2 for 5 hr to block SEC function and heat shocked cells at 42 C for 1 hr. Pol II ChIP-seq demonstrates that SEC inhibitors KL-1 and KL-2 block induction of known heat-shock-inducible genes such as FOS, HSPD1, HSPE1, and EGR1 (Figures 5A, 5B, and S5A). Analysis of Pol II occupancy at 136 genes induced by heat shock under vehicle conditions (Figures 5C and S5B) demonstrates that KL-1 and KL-2 treatments led to an impaired heat shock response ( Figures 5D and 5E ).
KL-1 and KL-2 structures mimic the AFF4 pentapeptide LFAEP ( Figure 1C ) that is conserved across the AFF family in humans and in the sole Drosophila member, Lilliputian ( Figure 5F ). Therefore, we tested the effect of KL-1 and KL-2 in the heat shock response in Drosophila S2 cells. As shown in Figure 5G , treatment of S2 cells with KL-1 and KL-2 attenuated heat shock induction of the 215 heat-shock-induced genes in these cells ( Figure 5G ).
Since SEC interacts with, and is an essential coactivator for the HIV transactivator Tat (He et al., 2010; Sobhian et al., 2010) , we examined the effect of KL-1 and KL-2 in this process using the J-Lat 6.3 clone, a derivative of Jurkat cells that has an integrated HIV genome in which GFP replaces the HIV nef gene (Jordan et al., 2003) . In this system, the activation of the HIV genome can be achieved by treatment with 10 nM phorbol 12-myristate 13-acetate (PMA), and the expression of the HIV genome can be monitored with GFP fluorescence ( Figure S5C ). Treating cells with 20 mM KL-1 or KL-2 resulted in a strong inhibition of GFP expression in J-Lat 6.3 cells after PMA induction as revealed by fluorescence-activated cell sorting (FACS) analysis ( Figure S5D ), and this inhibition is dose dependent ( Figure S5E ). ChIP-seq of Pol II in the J-Lat 6.3 cells confirmed that SEC inhib-itors block transcription elongation of the Tat-dependent integrated HIV genome ( Figure S5F ). Together, these studies demonstrate that KL-1 and KL-2 can inhibit SEC-mediated transcription elongation in both heat-shock-and Tat-mediated rapid-transcriptional induction models.
Chemical Inhibition of SEC by KL-1/KL-2 Downregulates MYC and MYC-Dependent Transcriptional Programs
We performed mRNA-seq of 293T cells after KL-1 and KL-2 treatments for 24 hr and found a large overlap in gene expression changes, with 1,911 genes being downregulated and 1,242 genes being upregulated by both treatments (Figures 6A-6C ). Gene ontology analysis revealed that RNA splicing-related factors, MYC target gene sets, and cell-proliferation-related terms are among the top enriched terms for downregulated genes in response to SEC inhibitors ( Figures 6D and S6A ). DNA repair, apoptosis, and cellular response to unfolded protein were modestly enriched terms for upregulated genes, suggesting a stress response of these cells after SEC inhibition ( Figure S6B ).
KL-1 and KL-2 treatments led to decreased expression of MYC, canonical MYC targets (Zeller et al., 2003) , and RNA splicing-related genes ( Figure 6C ), which were recently identified as direct MYC targets important for MYC-driven cancers (Hsu et al., 2015; Koh et al., 2015) . Interestingly, the PRMT5 gene, which encodes an enzyme responsible for methylation of splicing machinery proteins, is among the downregulated genes, suggesting that SEC inhibitors perturb the MYC-PRMT5 axis (Koh et al., 2015) , which could potentially be used to target splicing vulnerabilities in these cancers. We compared mRNAseq after SEC depletion with either AFF1 and AFF4 co-knockdown or ELL2 knockdown with gene expression changes after SEC chemical inhibition. We found that 1,221 genes out of the 1,911 (63.8%) SEC inhibitor-downregulated genes were significantly downregulated by SEC subunit depletion, and accordingly gene ontology analysis demonstrated enrichment for RNA splicing and MYC target gene terms ( Figures S6C and 6E ), which were also significantly downregulated after acute degradation of SEC subunit ENL .
These findings led us to investigate the potential of using SEC inhibitors in cancer cells exhibiting transcriptional addiction (Bradner et al., 2017) , such as those with high expression of MYC, which leads to increased transcription of downstream genes necessary for cancer cell proliferation (Lin et al., 2012; Sabò et al., 2014) . We used the previously characterized MYCamplified small cell lung carcinoma H2171 cells (Lin et al., 2012 ) and a corresponding low-MYC-expressing small cell lung cell line, SW1271 ( Figure 6F ). ChIP-seq of MYC protein in both H2171 and SW1271 cells confirms that H2171 has more MYC-occupied sites, consistent with a previous study (Lin et al., 2012) (Figures 6G and 6H) .
To elucidate the role of SEC in MYC-mediated transcriptional regulation, we performed ChIP-seq of SEC subunits in both H2171 and SW1271 cells and found SEC co-localized with MYC on chromatin ( Figure 6G ). Genome-wide analysis of MYC and SEC occupancy shows that H2171 cells have more MYC and SEC co-bound regions and increased occupancy of SEC ( Figures 6H-6J ), suggesting that SEC is involved in MYC-mediated transcriptional regulation in these cancer cells. We found that H2171 cells (Lin et al., 2012) are more sensitive to KL-1 and KL-2 treatments than SW1271 cells ( Figure 6K ), and knockdown of MYC in H2171 cells resulted in decreased sensitivity to SEC inhibition ( Figure S6E ), indicating that SEC inhibitors could be useful for abrogating the growth advantage of high MYC-expressing cancer cells.
Since MYC has been shown to recruit the P-TEFb complex (Rahl et al., 2010) and co-localizes with the P-TEFb containing SEC complex ( Figure 6I ), we examined the role of MYC in SEC recruitment and productive transcription elongation. We depleted MYC in 293T cells for 2 days and found that MYC depletion led to reduced chromatin occupancy of SEC subunits AFF1 and AFF4 (Figures S6F and S6G) . We also performed 4sU-FP-seq in MYC-knockdown cells and found that MYC depletion for 2 days results in reduced processivity at the MTR locus (Figure S6H) and observed a global defect in distance traveled after release from flavopiridol ( Figure S6I ). HMM analysis demonstrated that MYC knockdown led to decreased elongation rates ( Figure S6J ). These data suggest that SEC acts as a MYC cofactor by enhancing transcription processivity. (legend continued on next page)
KL-1/KL-2 Disruption of SEC Delays Tumor Progression and Improves Survival of Mice Bearing the MDA231-LM2 Tumor
To determine whether the SEC disruptors KL-1 and KL-2 could be used in vivo as possible cancer therapeutics through affecting the rate of transcription elongation, we employed the murine MDA231-LM2 tumor model ( Figure 7A ), which has been extensively characterized as a MYC-dependent tumor model (Hsu et al., 2015) and has been recently established in our lab . Both KL-1 and KL-2 could inhibit colony formation of MDA231-LM2 cells in vitro ( Figure S7A ), and both SEC disruptors increase apoptosis as shown by Annexin V staining (E) (K) MYC-amplified H2171 cells are more sensitive to KL-1 and KL-2 inhibition than MYC lowly expressed SW2171 cells. Both cell lines were treated with increasing concentrations of KL-1 and KL-2 for 3 days, and cell proliferation was measured with CellTiter-Glo (Promega) (n = 3-6). Data are represented as mean ± SD. See also Figure S6 . . 4 3 10 6 MDA231-LM2 cells were inoculated into fat pads of nude mice. 17 days after injection, when the tumor reached 100 mm 3 , mice were divided randomly into three groups. Drug treatments were performed once daily with 50 mg/kg KL-1, 10 mg/kg KL-2, or PBS (vehicle) for a total of 15 intraperitoneal injections. (B and C) KL-1 and KL-2 delay tumor growth in the MDA231-LM2 tumor mouse model. Average tumor sizes of the vehicle (n = 6), KL-1 (n = 7), and KL-2 (n = 5)treated groups were plotted from day 5 to day 36 after inoculation (B) . Representative tumors sizes are shown (C) . Data are represented as mean ± SD. (D) Dot plots of tumor sizes at day 36 after inoculation and vehicle, KL-1, and KL-2 treatment, indicating that SEC disruptors KL-1 and KL-2 delay tumor progression in vivo. A 2-way unpaired Student's t test was used for statistical analysis. Data are represented as mean ± SD. (E) Kaplan-Meier survival curves of vehicle, KL-1, and KL-2-treated nude mice transplanted with 4 3 10 6 MDA231-LM2 cells. 17 days after inoculation, vehicle (n = 6), KL-1 (n = 7), and KL-2 (n = 5) were administered daily for 15 intraperitoneal injections. Mice were euthanized when the tumor size reached 1,000 mm 3 . The p values were calculated using the log-rank test. See also Figure S7. ( Figure S7B ). We assessed the toxicity of KL-1 and KL-2 in mice with increasing doses and found that injection of 5 doses of 50 mg/kg KL-1 or 10 mg/kg KL-2 for 5 days does not result in significant weight loss in mice after monitoring for 35 days, and no obvious sign of sickness was observed during this period ( Figure S7C) .
To measure the potential of SEC inhibition in the MDA231-LM2 tumor model, we initiated injection of mice with SEC inhibitors on day 17 after inoculation, when the average tumor size reached 100 mm 3 ( Figure 7A ). After once-daily administration for 15 days, we further monitored tumor weights and mice were euthanized when the tumor size reached 1,000 mm 3 . Both KL-1 and KL-2 delayed tumor progression as monitored by tumor sizes ( Figures  7B-7D ). Our study demonstrated that both SEC inhibitors significantly extended survival of recipient mice ( Figure 7E ). Together, these data suggest that SEC disruptors could potentially be used to delay progression and improve the survival of MYC-dependent cancer.
DISCUSSION
SEC functions as a transcriptional cofactor that is required for driving high rates of transcription for the classic immediate-early genes, the heat shock genes under stress, and for production of the HIV provirus, and additionally contributes to oncogenesis by driving high rates of coordinated transcriptional programs such as occurs in MYC-amplified cancers Smith et al., 2011; Luo et al., 2012b) . Treatment of mammalian cells with KL-1 and KL-2 result in reduced levels of subunits of SEC AFF1, AFF4, and ELL2. Germline mutations that stabilize AFF4 cause the human developmental disorder CHOPS syndrome (Izumi et al., 2015) . Both AFF4 and ELL2 are targeted by the SIAH1 E3 ligase (Liu et al., 2012) . The SEC destabilizing property of KL-1 and KL-2 likely enhances the efficacy of our lead compounds in the transcription elongation assays and in vivo animal tumor model. Proteolysis-targeting chimera (PROTAC) methods that allow targeted degradation of proteins with small molecules have been shown to be much more efficacious than the smallmolecule inhibitor alone (Neklesa et al., 2017; Winter et al., 2015 Winter et al., , 2017 . For example, JQ1 and related compound IBET-151 bind to the bromodomains of BRD4 and block its interactions with acetylated histones on chromatin (Dawson et al., 2011; Filippakopoulos et al., 2010) . When JQ1-like molecules are fused to phthalimides to target BRD4 degradation by the endogenous cellular ubiquitin ligase cereblon, the loss of BRD4 protein obviates the need for constant interaction of JQ1 with BRD4 (Lu et al., 2015; Winter et al., 2015 Winter et al., , 2017 .
In this study, we found that SEC disruptors KL-1 and KL-2 could block transcription elongation in multiple SEC-dependent transcriptional models, demonstrating these compounds can be used a convenient chemical perturbation tool for the mechanistic and functional studies of SEC in other SEC-related cellular and developmental processes. Interestingly, we found that the MYC-dependent cancer cells are sensitive to the SEC inhibitors, providing the mechanistic finding that SEC is co-localized with MYC and exhibit increased occupancy in the MYC highly expressing cells, suggesting a dependency of transcription elongation for MYC-dependent cancers. Indeed, we also showed that SEC complex is involved in MYC-dependent transcription through promotion of transcription elongation rates and these SEC disruptors can be potentially used in vivo.
MYC hyperactivation induces transcriptional amplification and increases messenger RNA synthesis, which leads to an increased burden on the core spliceosome to properly process mRNA, suggesting that RNA splicing is a therapeutic vulnerability in MYC-driven cancer (Hsu et al., 2015; Lee and Abdel-Wahab, 2016) . RNA expression profiling analysis shows that KL-1 and KL-2 treatment leads to a significantly decreased output of the MYC transcriptional program, including RNA splicing-related genes including the PRMT5 gene, which is a key regulator among the MYC-upregulated genes (Bezzi et al., 2013; Koh et al., 2015) , suggesting that KL-1 and KL-2 could directly target MYC to lead to an impaired downstream MYC-PRMT5 axis.
KL-1 and KL-2 share the same scaffold and have similar activities toward SEC disruption and Pol II processivity, suggesting that this scaffold could function as a lead for future optimization. These leads already exhibit efficacy in impairing SEC function in rapid response models and delaying the progression of a MYCdependent tumor. Therefore, we anticipate that development of small-molecule inhibitors targeting SEC or otherwise slowing RNA Pol II processivity will be useful both for understanding the regulation of transcription elongation in cells and as therapeutic tools for the treatment of human disease including cancer.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: Plasmids, Peptides and Chemicals pGEX-2TK cyclin T1 (1-300) (Addgene P#432) was purchased from Addgene and used to express recombinant GST-CCNT1 in Rosetta cells. GST-CCNT1 (AA1-300) recombinant protein was purified with glutathione superflow agarose (Thermo, Cat# 25236). shRNAs for human AFF1 (TRCN0000021975 and TRCN0000330908), and AFF4 (TRCN0000426769 and TRCN0000015825) were obtained from Sigma. ELL2 was also depleted with shRNAs targeting the sequences AAC GCC AGA ATT ATA AGG ATG and AAA TGA TCC CCT CAA TGA AGT. Biotin labeled AFF4 peptide (AA32-67) and mutant AFF4 peptide abolishing the binding with CCNT1 were synthesized and purified (purity > 96%) by VCPBIO with further Trifluoroacetic acid removal. The sequence for wild-type AFF4 peptide is Biotin-GABA-SPL FAE PYK VTS KED KLS SRI QSM LGN YDE MKD FIG-amide and the mutant AFF4 peptide sequence is Biotin-GABA-SAA AAE PYK VTS KAA KLSS RIQ SAA GNY DEM KDF IG-amide where Biotin indicates N-terminal biotin labeling and GABA indicates a g-aminobutyric acid spacer. The candidate chemicals from the in silico screening were purchased from the vendors ChemDiv, ChemBridge and Enamine.
MDA231-LM2 Tumor Model
MDA231-LM2 tumor model was established as previously reported . Briefly, Six-week-old female athymic mice (nu/nu genotype, BALB/c background) were purchased from Envigo (Indianapolis, IN) and housed under aseptic conditions. All protocols, described below, were approved by the Northwestern University Institutional Animal Care and Use Committee. 4 3 10 6 MDA231-LM2 cells, in 0.4 mL of cell culture media with matrigel (BD Bioscience) were injected in the right mammary pad of mice under anesthetization by isoflurane. For the in vivo therapy-response study, mice were randomly assigned to vehicle (DMSO,) KL-1, and KL-2 treatment groups when the size of tumor reached 100 mm 3 . Mice were treated with drug administration by intraperitoneal injection at 50 mg/kg of KL1 and 10 mg/kg of KL2, with once daily administration for 15 days for 3 weeks. The tumor sizes were measured twice a week and the mice were euthanized when the tumor size reached 1000 mm 3 .
METHOD DETAILS
Chemical Synthesis
All chemical reagents were obtained from commercial suppliers and used without further purification unless otherwise stated. Anhydrous solvents were purchased from Sigma-Aldrich and dried over 3 Å molecular sieves when necessary. Normal phase flash column chromatography was performed using Biotage KP-Sil 50 mm silica gel columns and ACS grade solvents on a Biotage Isolera flash purification system. Analytical thin layer chromatography (TLC) was performed on EM Reagent 0.25 mm silica gel 60 F254 plates and visualized by UV light. Proton ( 1 H), and carbon ( 13 C) NMR spectra were recorded on a 500 MHz Bruker Avance III with direct cryoprobe spectrometer. Chemical shifts were reported in ppm (d) and were referenced using residual non-deuterated solvent as an internal standard. The chemical shifts for 1 H NMR and 13 C NMR are reported to the second decimal place. Proton coupling constants are expressed in hertz (Hz). The following abbreviations were used to denote spin multiplicity for proton NMR: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, brs = broad singlet, dd = doublet of doublets, dt = doublet of triplets, quin = quintet, tt = triplet of triplets. Low resolution liquid chromatography/mass spectrometry (LCMS) was performed on a Waters Acquity-H UPLC/ MS system with a 2.1 mm 3 50 mm, 1.7 mm, reversed phase BEH C18 column and LCMS grade solvents. A gradient elution from 95% water +0.1% formic acid/5% acetonitrile +0.1% formic acid to 95% acetonitrile +0.1% formic acid/5% water +0.1% formic acid over 2 min plus a further minute continuing this mixture at a flow rate of 0.85 mL/min was used as the eluent. Total ion current traces were obtained for electrospray positive and negative ionization (ESI+/ESI-). High-resolution mass spectra were obtained using an Agilent 6210 LC-TOF spectrometer in the positive ion mode using electrospray ionization with an Agilent G1312A HPLC pump and an Agilent G1367B autoinjector at the Integrated Molecular Structure Education and Research Center (IMSERC), Northwestern University.
Ethyl 4-(3-methoxyphenyl)-2,4-dioxobutanoate (2a): To a solution of diisopropylamine (1.4 mL, 10 mmol) in THF (33 mL) at À78 C was added n-BuLi (4.0 mL, 10 mmol). 3 0 -methoxyacetophenone (0.91 mL, 6.7 mmol) was added slowly, and the reaction was stirred at À78 C for 15 min. Diethyl oxalate (1.4 mL, 10 mmol) was added slowly, and the reaction stirred at À78 C for 1.5 hr. The reaction was slowly warmed to room temperature, then was quenched by the addition of 1M HCl (10 mL). The aqueous layer was extracted with EtOAc (3 3 75 mL) and then combined organic layers were washed with 1M HCl (10 mL), saturated aqueous NaHCO 3 (10 mL), water (10 mL), and brine (10 mL). The organic phase was dried over Na 2 SO 4 , decanted into a round bottom flask and concentrated by rotary evaporation. The crude material was recrystallized from EtOH to obtain 2a (0.764 g, 46% yield) as an off-white solid. 1 98, 169.47, 162.36, 160.17, 136.53, 130.03, 120.64, 120.38, 112.38, 98.38, 62.79, 55.67, 14.26 .
Ethyl 4-(4-fluorophenyl)-2,4-dioxobutanoate (2b): To a solution of diisopropyl amine (6.2 mL, 44 mmol) in THF (44 mL) at 0 C was added n-BuLi (16.2 mL, 40.5 mmol). The cloudy yellow solution was stirred at 0 C for 30 min., then cooled to À78 C. 4'-fluoroacetophenone (3.2 mL, 26 mmol) was added slowly along the sides of the flask and was stirred for 15 min. Diethyl oxalate (7.9 mL, 58 mmol) was added and the reaction stirred at À78 C for 1 hour. The mixture was warmed to room temperature and stirred for 20 min and the reaction was quenched by the addition of 1M HCl. The organic solvent was removed by rotary evaporation. The aqueous phase was extracted with EtOAc (3 3 75 mL) and the combined organic layers were washed with 1M HCl (25 mL), saturated aqueuos NaHCO 3 (25 mL), and brine (25 mL). The organic phase was dried over Na 2 SO 4 , filtered, and concentrated. The crude material was purified by flash column chromatography and recrystallized from EtOH to obtain 2b (3.38 g, 54% yield) as a yellow solid. 1 4-(3-methoxyphenyl)-2,4-dioxobutanoic acid (3a): To a solution of 2a (0.764 g, 3.05 mmol) in THF (15 mL) was added a solution of NaOH (1.22 g, 30.5 mmol) in 15 mL of water. The reaction stirred at room temperature for 15 min. The organic solvent was removed by rotary evaporation. The aqueous phase was extracted with Et 2 O (3 3 30 mL), then acidified with 1M HCl. The aqueous layer was extracted wtih EtOAc (3 3 50 mL), and the combined organic layers were washed with brine (50 mL), dried over Na 2 SO 4 , filtered, and concentrated by rotary evaporation to obtain 3a (0.450 g, 66% yield) as an off-white solid. 1 77, 174.75, 161.49, 160.07, 134.35, 130.09, 120.69, 120.49, 112.27, 95.27, 55.56. 4-(4-fluorophenyl)-2,4-dioxobutanoic acid (3b): To a solution of 2b (3.38 g, 14.2 mmol) in THF (47 mL) was added a solution of NaOH (5.68 g, 142 mmol) in 45 mL of water. The reaction stirred at room temperature for 15 min., then the organic solvent was removed by rotary evaporation. The aqueous phase was extracted with Et 2 O (3 3 50 mL), then acidified with conc. HCl. The aqueous layer was extracted with EtOAc (3 3 100 mL), and the combined organic layers were washed with brine (50 mL), dried over Na 2 SO 4 , filtered, and concentrated to obtain 3b (1.92 g, 64% yield) as an off-white solid. 1 90, 174.19, 166.49 (d, J = 257.7 Hz), 161.63, 130.62 (d, J = 9.5 Hz)*, 129.42 (d, J = 3.1 Hz), 116.44 (d, J = 22.1 Hz)*, 95.08. * Indicates two equivalent carbons with the same chemical shift that couple with 19 F. N-(5-chloro-2-methylphenyl)-4-(3-methoxyphenyl)-2,4-dioxobutanamide (4a): Acid 3a (0.400 g, 1.80 mmol) was dissolved in THF (9.00 mL) and 5-chloro-2-methylaniline (0.33 mL, 2.7 mmol) was added, followed by EEDQ (0.467 g, 1.89 mmol) . The reaction stirred at room temperature for 18 hr then was diluted with EtOAc. The organic phase was washed with 1M HCl (2 3 20 mL), saturated aqueous NaHCO 3 (2 3 20 mL), water (20 mL) and brine (20 mL). The organic phase was dried over Na 2 SO 4 , filtered, and concentrated. The crude material was recrystallized from MeOH to obtain 4a (0.412 g, 66% yield) as a yellow powder. 1 77, 179.73, 160.15, 159.08, 135.81, 134.96, 132.59, 131.55, 130.12, 126.23, 125.43, 121.28, 120.48, 120.38, 112.19, 94.18, 55.68, 17.20. N-(5-chloro-2-methylphenyl)-4-(4-fluorophenyl)-2,4-dioxobutanamide (4b): To a solution of 3b (0.208 g, 0.990 mmol) in THF (5 mL) was added 5-chloro-2-methylaniline (0.18 mL, 1.5 mmol), followed by EEDQ (0.257 g, 1.04 mmol). The reaction stirred at room temperature for 18 hr, then was diluted with EtOAc. The organic phase was washed wtih 1M HCl (3 3 10 mL), saturated aqueous NaHCO 3 (3 3 10 mL), water (10 mL), and brine (10 mL). The organic layer was dried over Na 2 SO 4 , filtered, and concentrated by rotary evaporation. The crude material was recrystallized from MeOH to obtain 4b (0.061 g, 59% yield) as a yellow powder. 1 81, 179.44, 166.34 (d, J = 256.6 Hz), 158.98, 135.76, 132.60, 131.57, 130.50 (d, J = 9.4 Hz)*, 129.91 (d, J = 2.85 Hz), 126.26, 125.48, 121.30, 116.42 (d, J = 22.2 Hz)*, 93.80, 17.19 . * Indicates two equivalent carbons with the same chemical shift that couple with 19 F.
In silico High-throughput Screening
In silico Filtering of The Small Molecule Database for Ligand Preparation The ZINC database (Irwin et al., 2012) , which contains approximately 41 million commercially available compounds, was used for virtual high-throughput screening (vHTS). All compounds in the ZINC library were subjected to a panel of PAINS substructures filters with Smiles ARbitrary Target Specifications (SMARTS) strings (Baell and Holloway, 2010) to eliminate promiscuous and non-drug-like molecules that interfere with functionality of the target proteins. Filtering generated a list of approximately 10 million commercially available compounds for further screening. The 10 million compound dataset was then subjected to the LigPrep module of Schrodinger (Small-Molecule Drug Discovery Suite 2017-2, Schrö dinger, LLC, New York) in OPLS2005 force field at pH 7.4 ± 1 (physiological pH) retaining the specific chirality. A low energetic 3D structure for each molecule was generated in this ligand preparation panel.
Protein Preparation for Small Molecule Screening and Grid Generation
The protein preparation (prot-prep) engine implemented in the Schrö dinger software suite was utilized to prepare the protein for small molecule docking simulations. Analysis of the tripartite complex crystal structure (4IMY.pdb) having a resolution 2.94 Å reveals the binding of the AFF4 protein to CCNT1, a subunit of P-TEFb. We observed that five terminal residues of AFF4 (L34, F35, A36, E37 and P38) are having good interactions with the binding groove of CCNT1containing the residues W221, Y224, L163, V164, R165, Y175, F176, D169, W207, W210 and E211. Furthermore, the mutation data of Y175, E211, D169, F176, R165, W210 and W207 of CCNT1 reported in the literature (Schulze-Gahmen et al., 2013) guided us to select the small molecule ligand-binding site. A 12 Å 3 grid was generated considering the centroid of the above mention critical residues in the CCNT1 groove.
Virtual Screening Workflow
For vHTS, we began with the curated library of approximately 10 million drug-like compounds described above and the OPLS 2005 force field was set. The ligand van der Waals radii was scaled to 0.80 Å with partial atomic charges < 0.15 esu. A three-tier Glide docking algorithm (Small-Molecule Drug Discovery Suite 2017-2, Schrö dinger, LLC) was employed that incorporates vHTS followed by Standard Precision (SP) and Extra Precision (XP) docking protocols. The output of this three-tier docking engine was analyzed using the XP-visualization tools by considering the interactions of the compounds with the critical residues reported above. Based on the docking scores, a list of 122 compounds was selected for cross validation using a 5-point structure focus pharmacophore generated by the pharmacophore module implemented in BIOVIA software considering the interactions of residues of AFF4 and Cyclin T1. Using the 5-point pharmacophore as the query, the glide hits were scored. Based on fitting scores and low energetics conformers, 67 hits were selected. We selected 40 available compounds having a Glide docking score < À6.0. The Glide score is a function of the binding energy (Small-Molecule Drug Discovery Suite 2017-2, Schrö dinger, LLC)
AlphaLISA Assay
The interaction of CCNT1-AFF4 was measured by Perkin Elmer's bead-based AlphaLISA assays. Recombinant GST-CCNT1 (1-300), which was purified by Glutathione Superflow Agarose from Rosetta cells, and AFF4 peptides were diluted in incubation buffer (25 mM HEPES, PH 7.4, 100 mM NaCl, 0.1% NP-40). GST-CCNT1 (AA1-300) and AFF4 peptides at indicated concentrations were mixed together with 0.5 mg of AlphaScreen Streptavidin Donor beads, and 0.5 mg of Glutathione AlphaLISA Acceptor Beads. For inhibition assays, inhibitors were added right after the mixture of CCNT1 and AFF4 peptide. Reactions were subsequently incubated for 2 hr with agitation in the dark. Plates were read with a Tecan INFINITE M1000 PRO. The dissociation constant Kd of CCNT1-AFF4 interaction was calculated based on the hyperbolic binding equation in Prism 7 (Graphpad). The IC 50 values of the KL-1 and KL-2 were calculated with a four-parameter sigmoid fitting equation in Prism 7 and converted to the inhibitory Constants (K i ) with the Cheng and Prusoff equation.
Heat Shock Induction
Heat shock of mammalian cells was performed using $70%-80% confluent HCT-116 cells by adding pre-heated (42 C) conditioned media collected from identically growing cells (Mahat et al., 2016b) . The heat shock cells were incubated at 42 C for 1 hour. After washing with PBS, the heat shock and non-heat shock HCT-116 cells were fixed with 1% formaldehyde in PBS for downstream ChIP-seq analysis. For heat shock induction of Drosophila S2 cells, the S2 cells were mixed with pre-heated medium to instantly increase the medium temperature from 24 C to 37 C and maintained in a water bath at 37 C for 10 min before fixation for ChIP-seq.
Induction of J-Lat 6.3 Cells The J-Lat 6.3 cell line was derived from human Jurkat cells with the integration of a full-length green fluorescent protein (GFP)encoding HIV-1 vector (HIV-R7/E À /GFP) under the control of the viral 5 0 -LTR (Jordan et al., 2003) . To measure the effects on Tatmediated HIV inducibility with flow cytometry, J-Lat 6.3 cells were incubated with 10 nM PMA (Phorbol 12-myristate 13-acetate) in the presence of vehicle or SEC inhibitors at the indicated concentrations for 17 hr. Cells were washed in PBS and GFP fluorescence was measured with a FACSVantage instrument (Becton Dickinson, San Jose, CA). Analysis was gated on live cells according to forward and side scatter. A two-parameter analysis to distinguish GFP-derived fluorescence from background fluorescence was used: GFP was measured in FL1 and cellular autofluorescence was monitored in FL2. The percentage of GFP-positive cells was calculated based on live cells (Jordan et al., 2003) . The J-Lat 6.3 cells were also induced with 10 nM PMA for 11 hr and then treated with Vehicle or SEC inhibitors for 6 hr prior to ChIP-seq analysis.
Chromatin Immunoprecipitation Sequencing
Chromatin Immunoprecipitation Sequencing (ChIP-seq) was performed according to a previously published protocol (Liang et al., 2015) . Briefly, cells were crosslinked with 1% paraformaldehyde for 10 min and were quenched with glycine for 5 min at room temperature. Fixed chromatin was sonicated with a Covaris Focused-ultrasonicator for 6 min and immunoprecipitated with the indicated antibody and Dynabeads Protein G. Libraries were prepared with the HTP Library Preparation Kit for Illumina (KAPA Biosystems) and sequenced on a NextSeq 500. ChIP-seq reads were aligned to the Drosophila genome (UCSC dm3) or human genome (UCSC hg19). Alignments were processed with Bowtie version 1.1.2, allowing only uniquely mapping reads with up to two mismatches within the 50 bp read. The resulting reads were extended to 150 bp toward the interior of the sequenced fragment and normalized to total reads aligned (reads per million, rpm). Peaks were called using MACS (model based analysis of ChIP-Seq) (Zhang et al., 2008) version 1.4.2 using default parameters. Ensembl version 75 transcripts were chosen with the highest total coverage from the annotated TSS to 200 nt downstream for protein coding genes that also have a RefSeq identifier, were at least 2 kb long, and 2 kb away from the nearest gene. The genes with SEC and Pol II occupancy were defined by the overlapping of peaks with Pol II and SEC peaks by MACS 1.4.2 using default parameters. For pausing indexes, the promoter region was defined as À200 bp upstream to 400 bp downstream, and the body region was the remainder of the entire gene body. The ratio of the average coverage (rpm) of the promoter over the average coverage of the gene body was then taken to be the pausing index. ECDF plots were made in R version 3.3.3 using the ecdf function. P-values were calculated with a two-sided Kolmogorov-Smirnov test. Heatmap tables were made for the indicated windows around the TSS or TES using the average coverage (rpm) in 25 bp & 50 bp bins (50 bp bins for 50 kb downstream of the TSS). Metagene tables were made by approximating the coverage across all genes to the same length. All ChIP-seq heatmaps were sorted by the decreasing coverage in indicated windows by the control samples and visualized using JavaTreeView version 1.6.4 (Saldanha, 2004) . Average profile plots were made by averaging the coverage for all genes using colMeans in R.
RNA-seq Analysis
Total RNA-seq reads were trimmed from the 3 0 end until the final base had a quality score > 30, using Trimmomatic version 0.33 (Bolger et al., 2014) and then aligned to the human genome (UCSC hg19, using Tophat version 2.1.0 (Kim et al., 2013) ) with the following options -no-novel-juncs-read-mismatches 2-read-edit-dist 2-num-threads 10-max-multihits 20 then post filtering for uniquely mapped reads using the NH flag. Protein coding genes from Ensembl version 75 that also had a RefSeq identifier were only considered for analysis. Raw read counts were normalized to rpm per sample and then displayed in the UCSC genome browser as bigWig-formatted coverage tracks. Exonic reads were assigned to specific genes from Ensembl release 75 using Bioconductor package GenomicRanges countOverlaps. The R Bioconductor package edgeR (Robinson et al., 2010) , version 3.12.0 was used to fit the data to a negative binomial generalized log-linear model and estimate a dispersion parameter. To filter out lowly expressed genes, genes had to have at least 1 count per million (c.p.m) in at least 2 samples in each comparison. The total number of uniquely mapped reads was provided to edgeR for the calcNormFactors normalization rather than the default column sums. An adjusted-p value threshold of 0.01 and a log 2 r.p.m cut off of 3 was used to identify genes significantly differentially expressed in one experimental condition relative to another. GO term analysis was done using Metascape .
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are presented as Mean ± SD. The sample sizes (n) in the figure legends indicate the number of replicates in each experiment and is provided in the corresponding figure legends. The peak or gene size (N) in the heatmaps indicates the number of peaks or genes included. For Figures S1I and S5E, One-Way ANOVA tests were performed with Prism 7 (GraphPad Software, La Jolla, CA) to determine the statistical significance. P value < 0.005 (**) was considered as highly significantly different, p value < 0.05 was considered as significantly different, n.s, not significantly different, p R 0.05. For Figures 2F, 2H , S2G, and S2H, the two-sided Kolmogorov-Smirnov test was performed for the ECDF curves and the p values were provided in each figure. For Figures S2E, S2F, 4G, S4E , 5E, and 5G, the statistical significance was determined by a two-sided Wilcoxon signed-rank test using R 3.3.3 package with the p values provided in each figure. For Figure 7D , a 2-tailed unpaired t test was used for comparison the tumor size between each treatment group. For Figure 7E , the Kaplan-Meier survival curves were plotted with GraphPad Prism 7 and the p values were calculated using the log-rank test.
DATA AND SOFTWARE AVAILABILITY
The accession number for the raw and processed ChIP-seq, RNA-seq, PRO-seq and 4sU-FP-seq data reported in this paper is GEO: GSE112608. (F) Treatment of HCT-116 cells with KL-1 and KL-2 reduced protein levels of SEC components AFF1 and AFF4 but not CDK9 or CCNT1. HCT-116 cells were treated with 20 mM of KL-1 or KL-2 for 6 hr, and the protein levels of AFF1, AFF4, CCNT1, CDK9 and Tubulin (load control) were determined by western blotting.
Supplemental Figures
(G and H) Treating cells with KL-1 and KL-2 results in reduced levels of AFF1 and AFF4. FLAG-AFF1 (G) and FLAG-AFF4 (H) were expressed under the Tetinducible promoter in HEK293T cells. Cells were treated with 20 mM of the indicated inhibitors for 6 hr for western blotting. (I) KL1 and KL-2 do not lead to reduced mRNA expression of SEC subunits AFF1, AFF4, ELL2, CCNT1 and CDK9 in HEK293T cells. RNA-seq was performed in HEK293T cells treated for 12 hr with 20 mM of the indicated inhibitors. The log 2 counts per million (CPM) SEC genes were calculated with HTseq. KL-1 and KL-2 had no significant effects on CCNT1, CDK9 and AFF1 expression, but modest increases in the mRNA levels of AFF4 and ELL2 were observed (n = 3). Unpaired two-way ANOVA was used for the statistical testes. **p < 0.05, ***p < 0.001. and Jurkat cells (C) . SEC inhibitor treatments result in increased Pol II occupancy around the TSS. Pol II density is plotted in a À2 kb and +2 kb window around the TSS. (D) K-means 3 clustered heatmap of Pol II fold change of the 6,840 genes after SEC inhibitor treatments. The region around the TSS is shown. Group I genes are preferentially affected by the SEC inhibitors. (E and F) Boxplot analysis of AFF1 (E) and AFF4 (F) occupancy at the three clusters from (D) . (G and H) ECDF plots of Pol II pausing indexes for all expressing genes in HCT-116 (G) and Jurkat cells (H) in the presence of vehicle or SEC inhibitors. (I and J) SEC inhibition results in a 5 0 shift of Pol II density near the Transcription End Site (TES) at the HSPA8 and SRSF4 genes. Pol II coverage in HEK293T cells is displayed in the UCSC genome browser. Figure S3 . Disruption of SEC Phenocopies Slow Pol II Mutants and Reduces Pol II Processivity, Related to Figure 3 (A) Identification of the 1,057 genes with typical Pol II termination signals around the TES. Pol II signals from WT Pol II mutant expressing cells were K-means clustered into 5 groups with a window of 15 kb around the TES. The expressing genes from clusters with a typical Pol II termination signals were selected and plotted. (B) SEC inhibitor treatments of the WT Pol II mutant expressing cells lead to a Pol II phenotype similar to slower Pol II mutant expressing cells as viewed at the 3 0 end of genes. (C and D) Time-dependent and dose-dependent shift of Pol II signals around the TES sites by KL-2 treatment (N = 1,057). (E) Genome browser tracks of Serine 2 phosphorylated (Ser2P) Pol II at the SRSF1 gene in HEK293T cells treated with vehicle or SEC inhibitors. SEC inhibitor treatments result in increased Pol II occupancy at the promoter-proximal region and increased occupancy of Ser2P Pol II in the gene body. (F and G) Metagene plot of Pol II Ser2P occupancy (F) and log 2 Ser2P/total Pol II ratio (G) for 6,840 well-expressed genes after SEC inhibitor treatments, indicating that disruption of SEC leads to altered Pol II dynamics, with increased CTD Ser2 phosphorylation ratio near TSS sites and decreased Ser2P occupancy after the annotated TES sites. (H) SEC inhibition results in decreased protein levels of the SEC subunit ELL2. 293T cells were treated with 20 mM of the indicated inhibitors for 6 hr before harvesting cells for western blotting.
(legend continued on next page) Figure S7 . SEC Disruptors Delay Tumor Progression and Improve Survival of MDA231-LM2 Tumor Mice, Related to Figure 7 (A) KL-1 and KL-2 inhibit the colony formation of MDA231-LM2 cells in vitro. 5 3 10 3 MDA231-LM2 cells were seeded in 6-well plates and treated with KL-1 or KL-2 at the indicated doses for 5 days. Crystal violet staining was performed to stain the colonies. (B) KL-1 and KL-2 induce apoptosis in MDA231-LM2 cells. Bar graph depiction of Annexin V positive MDA231-LM2 cells after 24 hr of KL-1 and KL-2 treatments at the indicated concentrations. Data are represented as mean ± SD. (C) Five intraperitoneal injections of 50 mg/kg of KL-1 or 10 mg/kg of KL-2 do not cause significant weight loss in mice after monitoring for 35 days. Each individual line indicates the weights of each mouse during toxicity test.
